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ABSTRACT 
Objective: The objective of this study was to prepare and characterize etoricoxib (ECB) loaded Soluplus® nanocomposites to improve its 
physicochemical properties. The effect of polymer and surfactant concentration on particle size, in vitro percentage dissolution efficiency and the 
anti-inflammatory activity of nanocomposites were also investigated.  
Methods: The nanocomposites were prepared by using a freeze-drying technique. The analytical evidence for the formulation of lyophilized 
nanocomposites in solid state were generated and confirmed by differential scanning calorimetry (DSC), fourier transformation infrared 
spectroscopy (FTIR), x-ray powder diffractometry (XPRD) and scanning electron microscopy (SEM). The in vitro drug release profile of 
nanocomposites was compared with pure ECB powder.  
Results: The nanocomposites of ECB were contained in a nano range with particle size and zeta potential of 63.5 nm and 46.5 mv, respectively. The 
solubility and dissolution of the nanocomposites were significantly (p<0.001) improved as compared to ECB alone, evidenced by decreased log P 
values (1.90±0.002) of the nanocomposites. The characterization studies revealed the formation of amorphous nanocomposites of ECB with 
existence of physical interactions between drug and polymer. The anti-inflammatory activity of nanocomposites evaluated by carrageenan-induced 
rat paw edema model demonstrated non significant (p>0.05) increase in anti-inflammatory activity as compared to pure ECB. 
Conclusion: From the results, it could be concluded that the formation of ECB nanocomposites with Soluplus® could be an effective and alternative 
approach to modify the physicochemical properties of ECB.  
Keywords: Etoricoxib, Soluplus®, Nanocomposites, Physicochemical properties, Anti-inflammatory activity 




The formation of the nanocomposite of the drug is one of the most 
widely used techniques to enhance the solubility and dissolution 
rate of poorly soluble drugs [1, 2]. Nanocomposite is a multiphase 
solid material which contains one of the phases and has one, two or 
three dimensions of less than 100 (nm) [3]. Structures having nano-
scale, repeat distances between the different phases that make up 
the material. Polymer nanocomposites have attracted interest in the 
last few decades, providing scope for improvement of 
physicochemical properties, of poorly water-soluble drugs.  
Many molecules currently under development fall in BCS 
(Biopharmaceutical Classification System) class II category, i.e. low 
solubility and high permeability [4] and generally show dissolution 
rate-limited absorption. Etoricoxib (ECB) (5-chloro-2-[6-methyl 
pyridine-3–yl]-3-[4-methysulfonylphenyl] pyridine) (NSAID) is 
regarded as second generation coxib because of its higher selectivity 
for COX-2 inhibition than celecoxib and rofecoxib. It has poor 
solubility [5, 6]. However, very low aqueous solubility and poor 
dissolution of the coxibs can cause formulation problems and limit 
their therapeutic application by delaying the rate of absorption and 
onset of action [7]. Earlier Papers have reported that the 
improvement in the physicochemical properties of poorly water-
soluble drugs could be achieved by the use of surfactants [8], 
inclusion complexation [9, 10], use of polymorph [11], and 
amorphous form of drug micronization [12], and solid dispersion 
[13, 14]. Improving oral bioavailability of the drugs given as solid 
dosage forms still remains a challenge for the formulation scientists 
due to solubility problems. Hence, improving their dissolution 
characteristics is of prime significance in order to establish its 
optimal therapeutic efficacy [15]. 
Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene 
glycol grafted copolymer) is a novel amphiphilic polymeric 
solubilizer, with both hydrophilic and lipophilic properties. Due to 
its bi-functional nature, it is expected to act as an excellent matrix to 
dissolve the drug in an aqueous medium. This polymer is a novel 
polymer specially designed for fourth-generation solid solutions 
towards dissolution enhancement [16] and can increase the 
solubility and bioavailability of poorly soluble drugs. Soluplus® is an 
ideal for formulating novel drug substances [2, 15]. 
Insptite of powerful analgesic and anti-inflammatory potential [17, 
18], ECB exhibits a delayed rate of absorption [17]. Therefore, 
efforts were made to improve the physicochemical properties of ECB 
using solid dispersion [19-21], drug amorphization [22-24], 
cyclodextrin complexation [25, 26] and spherical crystallization 
technique [27]. In this article, the formation of nanocomposites of 
ECB were attempted with Soluplus® to evaluate it for 
physicochemical properties as well as anti-inflammatory activity.  
The aim of this work was to investigate the physicochemical 
properties and anti-inflammatory activity of ECB by formulating it 
into its nanocomposites with soluplus® in the presence of tween 80. 
The aim was extended to study the effect of polymer and surfactant 
concentrations on the particle size and percentage dissolution 
efficiency of nanocomposites of ECB, prepared by freeze-drying 
technique. The lyophilized nanocomposites were characterized by 
differential scanning calorimetry (DSC), fourier transformation 
infrared spectroscopy (FTIR), x-ray powder diffractometry (XPRD), 
scanning electron microscopy (SEM), saturation solubility, partition 
coefficient determination (log P) and drug content uniformity. The 
dissolution performance of pure drug and nanocomposites were 
further examined in phosphate buffer (pH 7.4). The optimized batch 
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and pure drug were further evaluated for their anti-inflammatory 
activity by carrageenan-induced rat paw edema model.  
MATERIALS AND METHODS 
Materials 
ECB was generously gifted by Ranbaxy, Mumbai, India. Soluplus® 
was obtained as a gift sample from BASF, Mumbai, India. Tween 80 
and methanol were purchased from Loba Chemie Pvt., Ltd. Mumbai, 
India. Analytical grade reagents and glass distilled water were used 
throughout the experimental procedures. The substances were used 
directly without further purification. 
Preparation of ECB loaded nanocomposites by freeze-drying 
method 
The nanocomposites were produced by the freeze-drying method. 
Firstly, nanoemulsions of ECB in Soluplus®were prepared using 
probe ultrasonicator. The drug and polymer were dissolved in 
methanol in different polymer ratios to form the organic phase. 20 
ml of distilled water with different ratios of Tween 80 surfactant 
formed the aqueous phase. The two mixtures were sonicated for 15 
min. Using a syringe, the organic phase was slowly dropped into the 
aqueous phase. A continuous probe ultrasonication in an ice bath 
was used for effective homogenization of the two phases. The 
mixture was then magnetically stirred continuously for 24 h at room 
temperature (25°C±2) for removal of methanol, and then the 
mixtures were frozen for 25 h in a deep freezer (ELCOLD, Denmark) 
at -80°C. Then the frozen mixtures were lyophilized (DELVAC-mini 
Lyodel, India) at -80°C and gently ground to obtain free-flowing 
powders. The powders were then sieved though mesh of 100 µm 
sieve size and stored in desiccators until further analysis [15]. 
Determination of drug content 
Drug content was determined by dissolving prepared nano 
composites equivalent to 5 mg of a drug in 10 ml of methanol and 
then the volume was adjusted up to 50 ml with distilled water. The 
solution was sonicated for 15 min and filtered through 0.2 µm 
membrane filter. The aliquots were suitably diluted and absorbance 
was measured at 234.5 nm by using UV-visible spectrophotometer 
(Shimadzu 1800, Japan). 
Saturation solubility studies 
Saturation solubility studies were performed as follows: Excess 
amount of pure ECB drug and nanocomposites were added to 10 ml 
of distilled water in solubility tubes and shaken on a mechanical 
shaker at room temperature 25±2 °C for 24 h. Once the equilibrium 
was achieved, appropriate aliquots were withdrawn and filtered 
through 0.2 µm membrane filter and the filtrate was analyzed UV 
spectrophotometrically (Shimadzu 1800, Japan) at 234.5 nm [28]. 
The results of solubility studies were statistically validated using 
ANOVA (Instat, GraphPad software, Inc. Version 3.05). 
Particle size analysis  
The nanocomposites were characterized for particle size using 
Horiba nanoparticle size analyzer (HORIBA SZ-100 for windows [Z-
Types] Ver. 1.90, Kyoto, Japan). The particle size distribution was 
given by d (0.9), d (0.5), d (0.1) which were the particle size 
diameters determined at the 90th, 50th and 10th percentile of particle 
undersized, respectively [29, 30]. 
Zeta potential determination 
The surface charge was determined by measuring the 
electrophoretic mobility of nanocomposites by using Horiba Nano 
particle size analyzer (HORIBA SZ-100 for windows [Z-Types] Ver. 
1.90, Kyoto, Japan). The zeta potential was measured after dilution 
of the sample with distilled water at room temperature [29, 30]. 
Determination of partition coefficient (log P) 
10 ml each of octanol and water were added in glass tubes and 
allowed to stand overnight for 24 h at room temperature. Excess 
amount (equivalent to 25 mg) of pure drug and/or its 
nanocomposites were added in glass tubes and shaken on an 
incubator shaker (REMI-CIS 24 plus Incubator Shaker, Mumbai, 
India) for 24 h at 25°C. Then the mixtures were added in the 
separating funnel and allowed to stand about 6 h for equilibration. 
Aqueous and organic phases were separated and concentration of 
drug in the aqueous phase was analyzed UV spectrophotometrically 
(Shimadzu 1800, Japan) at 234.5 nm [31]. The partition coefficient 
was calculated by following formula, 
The partition coefficient (log P) = log (Coctanol/Cwater) …. (1) 
Where C is the concentration of the drug in octanol and/or water 
phase. 
In vitro drug release 
The dissolution studies of ECB and its nanocomposites were 
performed in triplicate in a dissolution test apparatus (ELECTROLAB 
dissolution apparatus, Mumbai, India) according to USP type II. 
Samples were placed in the dissolution vessel containing 900 ml of 
phosphate buffer (pH 7.4), maintained at 37±0.5 °C at 50 rpm 
according to US FDA guidelines. 60 mg of ECB or its equivalent 
amount of nanocomposites was added to 900 ml of phosphate buffer 
(pH 7.4). 5 ml of samples were withdrawn at appropriate time 
intervals. The volume of dissolution media was adjusted to 900 ml 
by replacing each 5 ml aliquot withdrawn with 5 ml of fresh 
phosphate buffer (pH 7.4) [21]. The solution was immediately 
filtered through membrane filter paper 0.2 µm, and adequately 
diluted if necessary and analyzed spectrophotometrically at 288 nm 
(Shimadzu 1800, Japan). The data obtained through dissolution 
studies were statistically analyzed by ANOVA (Instat, GraphPad 
software, Inc. Version 3.05). 
DSC analysis 
DSC analysis of pure ECB, Soluplus® and an optimized batch of 
nanocomposites were performed using DSC analyzer (TA 
Instruments, SDT Q600 USA). A sample (5 mg) was heated under a 
nitrogen atmosphere at a heating rate of 10 °C/min over the 
temperature range of 0-275 °C.  
FTIR analysis 
Attenuated Total Reflectance (ATR) is a sampling technique used in 
conjunction with infrared spectroscopy, which enables samples to 
be examined directly in the solid or liquid state without further 
preparation. Infrared spectra of all samples were obtained by using 
ATR (BRUKER–ECO–ATR–ALPHA, Germany). The samples were 
directly placed on sample pan and analyzed from 600 to 4000 cm-1 
spectral range with 24 scans. 
XRPD studies 
The XRPD patterns of pure ECB, Soluplus® and an optimized batch of 
nanocomposites were recorded by using X-ray diffractometer 
(BRUKAR–D2 PHA–SER, Germany) with tube anode Cu, over the 
interval 10-90°/2Ɵ. The operational data was as follows: Generator 
tension (voltage) 30 kV, Generator current 10 mA. 
SEM analysis 
The surface morphology of the drug and optimized batch of 
nanocomposites were evaluated by a scanning microscope (SEM-
JOEL Instruments, JSM-6360, Japan) operated at an acceleration 
voltage of 20 kV and obtained micrographs were examined at ×200, 
×500 magnifications. 
Anti-inflammatory activity of ECB nanocomposites 
All experiments were approved by the Institutional Animal Ethics 
Committee (the Approval No. RCP/IAEC/16-17/P09 dated 
12.06.2017) and were carried out according to the guideline of the 
CPCSEA (committee for the purpose of control and supervision of 
experiments on animals) Healthy Wistar albino rats (procured from 
National institute of Biosciences, Bhor, Pune) of either sex weighing 
275-250 g were used in the present study The animals were housed 
comfortably in a group of six in a single clean plastic cage with a 
metal frame lid on its top. They were housed under standard 
environmental conditions of temperature A 12:12 h light, dark cycle 
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was followed. All animals had free access to water and standard 
palletized laboratory animal diet feed.  
Anti-inflammatory activity of nanocomposites was performed by 
using carrageenan-induced rat paw edema method. Male Wistar 
rats selected for the study were randomized based on their body 
weight and divided into six different groups consisting of 6 
animals each. Rats were injected subcutaneously (S.C.) by injection 
of carrageenan (0.1 ml of 1 % solution in normal saline) into the 
plantar side of the left hind paw. The paw was marked with ink at 
the level of the lateral malleolus. The paw volume was measured 
up to the mark using digital plethysmometer before (-1 h) and at 1, 
2, 3, 4, and 6 h after injection of carrageenan for all the animals. 
Paw edema volume was calculated by subtracting-1 h paw volume 
from the respective paw volumes at l, 2, 3, 4, and 6 h [32-36]. 
RESULTS AND DISCUSSION  
Otimization of batches 
ECB and different ratios of polymer: surfactant batch was optimized 
based on its saturation solubility data. 
Saturation solubility studies 
The results of saturation solubility studies of all nanocomposites of 
ECB are shown in table 1. It was evident that solubility of all batches 
was enhanced significantly (p<0.001) as compared to pure drug alone. 
The aqueous solubility of the optimized batch (F6) was found to be 
6.90 fold increase, as compared to pure ECB. Hydrophilicity of the 
polymer with a simultaneous reduction in particle size might have 
contributed for a substantial increase in solubility of formulations.
 
Table 1: Particle size and solubility data of various batches for optimization 
Batch code Drug to polymer ratio (mg: mg) Amount of surfactant added (ml) Particle size (nm) Saturation solubility (µg/ml)* 
ECB    42.44±0.20 
F1 1:1 0.005 15.7 254.66±2.30** 
F2 1:3 0.005 3.3 282.22±2.77** 
F3 1:1 0.0095 149 197.77±2.03** 
F4 1:3 0.0095 29.9 282.88±3.79** 
F5 1:1 0.014 64.2 274.66±2.66** 
F6 1:3 0.014 63.5 292.88±2.77** 
ECB: etoricoxib; *mean±SD (n = 3): SD standard deviation; **significant differences compared to pure ECB (p<0.001). 
 
Percent drug content 
Percentage drug content of the freeze-dried optimized batch (F6) 
was found to be 99.1±0.45 (w/w). 
Particle size analysis 
The particle size analysis revealed that the nanocomposites of ECB 
were found to be in nano range (table 1). The particle of pure ECB 
was found to be in micron range 2.31 µm with a polydispersity index 
(PI) of 0.70. The particle size of the optimized batch F6 was 
measured to be 63.5 nm (fig. 1). However, nonuniform distribution 
of particles was noticed. Using the freeze-drying technique, the size 
of the pure drug was significantly reduced in nano size [29, 30]. 
 
 
Fig. 1: The particle size distribution of optimized batch (F6); 
PSA: particle size analysis 
 
Zeta potential determination 
Drug and optimized batch F6 were subjected to zeta potential 
analysis (fig. 2). The particles with zeta-potential values more 
positive and more negative than+30mV and-30mV, respectively, 
are generally considered stable. According to the data, the zeta 
potential was found to be-65.5 and-46.5 mV, respectively, 
indicating the formation of stable nanocomposites. The negative 
value of zeta potential indicates a negative charge on the droplets 
[29, 30].  
 
Fig. 2: Zeta potential of drug (ECB), optimized batch (F6); ECB: 
etoricoxib 
 
Determination of partition coefficient (log P) 
The log P value of ECB and optimized batch (F6) were found to be 
2.37±0.009 and 1.90±0.002 respectively (p ˂ 0.001). The decreased 
log P value of optimized batch (F6) compared to ECB, clearly 
indicated an enhancement in hydrophilicity of optimized batch (F6). 
In vitro drug release 
The release rate profiles were expressed as the percentage of 
drug released (vs.) time (fig. 3). It was evident that 
nanocomposites have improved the dissolution rate of ECB 
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significantly. Table 2 shows % drug dissolved in 5 min (DP5), 15 
min (DP15), 30 min (DP30) and 45 min (DP45) for ECB and its 
nanocomposites batches (F1 to F6). The dissolution efficiency 
values (DE45) at 45 min have been reported and compared 
statistically. The dissolution efficiency (DE) is defined as the 
area under dissolution curve up to the time t expressed as a 
percentage of the area of rectangle described by 100% 
dissolution in the same time [37]. The optimized batch (F6) of 
ECB showed faster dissolution than pure ECB alone. The % 
release of ECB was 66.75±0.60 from optimized batch (F6) within 
15 min (DP15). However, the release of ECB from pure ECB was 
only 7.45±0.06 within 15 min. Thus optimized batch (F6) of ECB 
with soluplus® had significantly improved the dissolution rate of 
the pure ECB (DE45: 59.65±0.26, p<0.001). 
 
Table 2: The dissolution data of pure ECB and its nanocomposites batches in phosphate buffer (pH 7.4) at 37±0.5 °C 
Batch code DP5*±SD DP15*±SD DP30*±SD DP45*±SD DE45*±SD 
ECB 2.65±0.08 7.45±0.06 11.88±0.05 15.81±0.24 8.82±0.06 
F1 31.80±0.30 45.80±0.52 59.55±0.15 62.85±1.22 48.49±0.32** 
F2 26.55±0.75 43.85±1.27 58.40±0.60 68.50±0.60 48.34±0.35** 
F3 28.55±0.82 35.85±0.39 46.56±0.40 48.80±0.52 38.18±0.14** 
F4 37.50±0.25 57.05±0.52 67.20±0.79 68.85±0.98 55.61±0.33** 
F5 37.66±0.96 50.85±0.65 62.70±0.60 66.75±0.60 52.97±0.19** 
F6 37.10±0.45 66.20±0.52 68.60±0.67 71.00±0.62 59.28±0.43** 
ECB: etoricoxib; *mean±SD standard deviation (n = 3); DP: % drug dissolved; % DE: % dissolution efficiency; indicates p value compared to pure 
ECB (p<0.001), i.e. **significant. 
 
 
Fig. 3: The dissolution profile of ECB and F1 to F6 batches at 37±0.5°C; ECB: etoricoxib 
 
DSC analysis 
DSC thermogram of ECB, polymer and optimized batch (F6) are 
shown in (fig. 4). ECB showed a distinct melting endotherm at 138 
°C. The polymer Soluplus® showed a glass transition (Tg) endotherm 
at 62.58 °C. The nanocomposites of the optimized batch (F6) have 
shown the complete disappearance of pure ECB melting peck; 
indicating the decrease of the crystalline nature of the drug. 
Enhanced solubility and faster dissolution rates of the drug are 
known to result from the transformation of the stable crystalline 
state of the drug to some amorphous state in the formulations. 
FTIR analysis 
Fig. 5 illustrates the FTIR spectra of ECB, polymer and optimized 
batch (F6) studied by ATR-IR spectroscopy. IR spectrum of ECB is 
characterized by principal absorption peaks at 3052.89 cm-1 (C-H 
stretch aromatic benzene), 2882.17 cm-1 (C-H stretch aliphatic CH3 
asym), 1669.75 cm-1,1595.07 cm-1and 1492.31 cm-1(C= C aromatic), 
1669.75 cm-1(C=N), 1138.04 cm-1 (S=O sulphonyl), 1082.77 cm-1 (C-
Cl), 837.98 cm-1 (p-substituted benzene) and 736.68 cm-1 (pyridine). 
IR spectrum of Soluplus® exhibited characteristic IR bands at 3337.07 
cm-1 and 3280.18 cm-1(O-H stretching), 2916.80 cm-1 (aliphatic-CH 
stretching), 1732.15 cm-1and 1634.93 cm-1(C=O stretching). 
In IR spectrum of the optimized batch (F6), the peak of ECB at 
3052.89 cm-1 (C-H stretch aromatic benzene) was completely 
disappeared while other peaks were found to be diffused. The IR 
bands at 1082.77 cm-1 (C-Cl), 2882.17 cm-1 (C-H stretch aliphatic CH3 
asym) were shifted towards lower frequency 1084.39 cm-1and 
2890.81 cm-1, respectively. The peaks of soluplus®at 3337.07 cm-
1(O-H stretching) were shifted to 3323.59 cm-1. The intensity of the 
band at 1595.07 cm-1(C= C aromatic) was also prominently 
decreased, indicating the existence of physical interactions. 
 
 
Fig. 4: DSC thermograms of drug (ECB), Soluplus®(polymer), 
optimized batch (F6); ECB: etoricoxib 
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Fig. 5: FTIR spectra of drug (ECB), Soluplus®(polymer), 
optimized batch (F6); ECB: etoricoxib 
 
XRPD studies  
The XRPD pattern of ECB displayed intense and sharp peaks, 
indicating its crystalline nature. ECB (fig. 6) showed 2Ɵ values and 
peak intensities at 15.44 °(594), 16.45 °(1144), 16.31 °(635), 22.69 
°(626), and 29.16 °(553). A typical halo-pattern was noted for 
Soluplus® (fig. 6), indicated its amorphous character. The peak 
height at 16.74 ° (2Ɵ) was used for calculating the relative decrease 
in crystallinity (RDC) of ECB in optimized batch (F6) (fig. 6), as 
peaks of ECB with the highest intensity (16.45°) disappeared in 
these nanocomposites. However, other peaks of ECB were also 
disappeared. The disappearance of intense peaks of ECB in 
optimized batch (F6) suggested a loss of the crystallinity and 
possibility of the presence of some amorphous entities of ECB in 
these nanocomposites [38, 39]. 
 
Fig. 6: XRPD patterns of of drug (ECB), soluplus®(Polymer), 
optimized batch (F6); ECB: etoricoxib 
 
SEM analysis 
The surface morphology of the pure ECB powder, an optimized batch of 
nanocomposites (F6) is shown in (fig. 7). ECB was characterized by the 
presence of rod-shaped, uneven rough and broken particles. The surface 
morphology of freeze-dried nanocomposites (F6) batch showed 
irregular particles of some amorphous aggregates with narrow particle 
size distribution and the original morphologies of pure ECB decreased. 
The nanocomposites of ECB exerted amorphous form with a reduction 
in the particle size, thus remarkably affecting the drug solubility and 
dissolution rate [40]. 
  
 
Fig. 7: SEM of drug (ECB) A1, A2; optimized batch (F6) C1, C2; ECB: etoricoxib 
 
Anti-inflammatory activity of ECB nanocomposites  
From the histogram (fig. 8) and table 3, at 0 h drug showed negative % 
inhibition due to poor absorption. However, at 0 h, F6 batch showed % 
inhibition indicating faster absorption of nanocomposites due to particle 
size reduction of drug and enhancement of solubility. There was no 
significant difference between drug and F6 at all hrs. Hence, the result 
concluded that the nanocomposites showed the same activity [34-36]. 
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Fig. 8: Histogram of % inhibition of ECB; F6 (optimized batch nanocomposites); ECB: etoricoxib 
 
Table 3: The anti-inflammatory activity by carrageenin-induced hind paw edema in rat 
Hours/System  Control ECB F6** 
0 Increase in paw volume* ml 1.87±0.007 2.06±0.28 1.85±0.16 
% inhibition* - -10.16 1.06 
1 Increase in paw volume* ml 2.50±0.14 2.16±0.26 1.97±0.05 
% inhibition* - 13.6 21.2 
2 Increase in paw volume* ml 2.66±0.02 2.27±0.32 2.08±0.07 
% inhibition* - 14.66 21.80 
3 Increase in paw volume* ml 2.80±0.042 2.45±0.37 2.36±0.08 
% inhibition* - 14.64 15.35 
4 Increase in paw volume* ml 2.98±0.04 2.45±0.37 2.36±0.08 
% inhibition* - 17.28 20.80 
6 Increase in paw volume*ml 3.01±0.02 2.39±0.39 2.34±0.07 
% inhibition* - 20.59 22.25 
*mean±SD (n=6); SD standard deviation, **non-significant difference compared to pure ECB (p ˃ 0.05); ECB: etoricoxib, F6: optimized batch F6 
 
CONCLUSION 
The present investigation demonstated successful formation of the 
nanocomposites of ECB using amphiphilic polymer soluplus®by 
freeze-drying technique. Freeze drying technique has shown a 
significant reduction of particle size and improved the solubility and 
dissolution rate of the drug. The characterization of freeze-dried 
nanocomposites revealed that the drug was converted into an 
amorphous form. The application of freeze-drying technique gave a 
statistically systematic approach for the formulation of 
nanocomposites with desired particle size and percentage drug 
release within 45 min. The formulation F6 batch was selected as an 
optimized batch with desired properties and produced non 
significant anti-inflammatory activity in rats. Thus, it could be 
concluded that the use of freeze-drying technology, amphiphilic 
carrier, and tween 80 to prepare polymeric nanocomposites could 
improve physicochemical properties of ECB. 
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